Dexmedetomidine Attenuates Inflammation and Pancreatic Injury in a Rat Model of Experimental Severe Acute Pancreatitis via Cholinergic Anti-Inflammatory Pathway
Severe acute pancreatitis (SAP) is a life-threatening condition characterized by systemic inflammatory response syndrome (SIRS), multi-organ dysfunction, and high mortality rates ranging from 30% to 60%. Despite advances in understanding its pathophysiology, effective anti-inflammatory therapies remain limited. This study investigates the protective effects of dexmedetomidine (DEX), a selective alpha-2 adrenergic receptor agonist, in a rat model of SAP induced by sodium taurocholate. The findings reveal that DEX mitigates pancreatic injury and systemic inflammation through mechanisms involving the cholinergic anti-inflammatory pathway, specifically via vagus nerve activation and alpha-7 nicotinic acetylcholine receptor (α7nAChR)-dependent signaling.
Pathogenesis of SAP and the Role of Inflammation
SAP develops in approximately 20% of acute pancreatitis (AP) cases, driven by excessive inflammatory responses that lead to pancreatic necrosis and systemic complications. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) amplify local and systemic inflammation, contributing to organ failure. Current therapeutic strategies focus on supportive care, as previous attempts to directly target inflammatory mediators have shown limited clinical success. Emerging evidence highlights the cholinergic anti-inflammatory pathway—a neuro-immune interaction mediated by the vagus nerve, acetylcholine, and α7nAChR—as a potential therapeutic target. Activation of this pathway suppresses cytokine release and attenuates inflammation in conditions like sepsis and ischemia-reperfusion injury.
Experimental Design and Methodology
The study utilized male Sprague-Dawley rats (280–350 g) to evaluate DEX’s effects on SAP. Sodium taurocholate (3.5%, 1 mL/kg) was retrogradely infused into the cholangiopancreatic duct to induce SAP. DEX (30 μg/kg) was administered intraperitoneally 30 minutes before SAP induction. To investigate the cholinergic pathway’s involvement, two interventions were employed: (1) unilateral cervical vagotomy (VGX) prior to DEX administration, and (2) pre-treatment with α-bungarotoxin (α-BGT, 1 μg/kg), a selective α7nAChR antagonist. Sham-operated rats served as controls.
Key endpoints included serum levels of TNF-α, IL-6, and amylase measured six hours post-SAP induction. Pancreatic tissue damage was assessed histologically using hematoxylin and eosin (H&E) staining and scored according to Schmidt criteria, which evaluate edema, necrosis, hemorrhage, inflammation, and perivascular infiltrate. Vagal nerve activity was recorded using bipolar electrodes connected to a BL-420F Data Acquisition System to quantify discharge frequency and amplitude.
DEX Reduces Systemic Inflammation and Pancreatic Injury
SAP induction resulted in significant increases in serum TNF-α (256.1 ± 42.4 pg/mL vs. control: 74.3 ± 8.6 pg/mL), IL-6 (421.7 ± 48.3 pg/mL vs. control: 98.2 ± 20.4 pg/mL), and amylase (3186.4 ± 245.2 U/L vs. control: 252.6 ± 20.3 U/L). Pre-treatment with DEX markedly reduced these markers (TNF-α: 174.2 ± 30.2 pg/mL; IL-6: 293.3 ± 46.8 pg/mL; amylase: 2102.3 ± 165.3 U/L), demonstrating its anti-inflammatory and pancreas-protective effects.
Histopathological analysis corroborated these findings. SAP rats exhibited severe edema, hemorrhage, neutrophil infiltration, and acinar cell necrosis. DEX pre-treatment preserved pancreatic architecture, with significantly lower Schmidt scores (pathology score reduced by ~40% compared to SAP group). However, vagotomy or α-BGT administration abolished DEX’s benefits, restoring cytokine levels and histopathological damage to levels observed in untreated SAP rats.
Vagal Activation and α7nAChR Dependency
The cholinergic anti-inflammatory pathway’s role was further elucidated through vagus nerve recordings. SAP reduced vagal discharge frequency (332.4 ± 25.1 Hz vs. control: 412.3 ± 35.6 Hz) and amplitude (20.5 ± 2.9 μV vs. control: 28.4 ± 4.7 μV). DEX restored vagal activity, increasing frequency to 456.8 ± 50.3 Hz and amplitude to 33.4 ± 5.3 μV. This enhanced vagal signaling likely potentiates acetylcholine release, which binds α7nAChR on immune cells to inhibit cytokine production. The necessity of α7nAChR was confirmed by α-BGT pre-treatment, which blocked DEX’s anti-inflammatory effects, underscoring the receptor’s critical role.
Mechanistic Insights and Clinical Implications
DEX’s protective effects are attributed to its dual action on the central nervous system and peripheral immune response. As an alpha-2 agonist, DEX reduces sympathetic tone, shifting autonomic balance toward parasympathetic (vagal) dominance. Enhanced vagal activity increases acetylcholine release, activating α7nAChR on macrophages and other immune cells. This interaction suppresses NF-κB signaling, a key regulator of pro-inflammatory cytokine production. The study provides direct evidence linking DEX’s anti-inflammatory properties to vagal activation and α7nAChR engagement, offering a mechanistic foundation for its use in SAP.
Clinically, DEX is widely used for sedation in critical care settings. Its ability to modulate the cholinergic pathway presents a therapeutic advantage, as it may concurrently alleviate inflammation while minimizing sedation-related complications. The findings suggest that DEX could be repurposed as an adjunct therapy for SAP, particularly in early stages where controlling inflammation is pivotal. However, the study’s prophylactic DEX administration limits direct translation to clinical scenarios, where treatment often begins after SAP onset. Future research should explore DEX’s efficacy in therapeutic (post-onset) models and investigate downstream α7nAChR signaling pathways, such as JAK2/STAT3 modulation.
Conclusion
This study demonstrates that DEX attenuates pancreatic injury and systemic inflammation in experimental SAP through vagus nerve-dependent activation of the cholinergic anti-inflammatory pathway. The α7nAChR is essential for mediating these effects, as shown by the abolition of protection with α-BGT or vagotomy. By enhancing vagal discharge and leveraging α7nAChR signaling, DEX reduces pro-inflammatory cytokines and mitigates histopathological damage. These findings highlight DEX’s potential as a therapeutic agent for SAP and underscore the importance of neuro-immune interactions in managing inflammatory diseases.
doi.org/10.1097/CM9.0000000000000766
Was this helpful?
0 / 0